MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. is positioned for significant revenue growth, with projections indicating that volixibat sales could surge from $18 million in 2027 to $854 million by 2033, contributing to an anticipated core business revenue exceeding $1 billion. Livmarli is expected to experience robust market demand, potentially increasing its revenue to over $800 million by 2031, driven by strong adoption rates in both Alagille syndrome and Progressive Familial Intrahepatic Cholestasis. Additionally, the company’s diverse portfolio of approved drugs, which includes Cholbam and Ctexli, coupled with favorable market dynamics and the potential for extended exclusivity, supports a positive outlook for its financial performance.

The outlook for Mirum Pharmaceuticals Inc. appears negative due to several critical factors that may adversely impact its financial performance. The possibility of unexpected safety events, insufficient drug efficacy, and the need for more frequent or less favorable equity issuances due to elevated operating expenses and cash burn can hinder the company's financial stability and growth prospects. Additionally, the risk of regulatory setbacks, including failure to obtain approvals for pipeline candidates and the emergence of safety concerns, poses significant threats to Mirum's future revenue generation and overall market position.